Back to Search
Start Over
Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists
- Source :
- Pharmacological Research (2019)
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Cancer immunotherapy has come of age with the advent of immune checkpoint inhibitors. In this article we review how agonists for receptors of the innate immune system, the Toll-like receptors and the RIG-I-like receptors, impact anticancer immune responses. Treatment with these agonists enhances the activity of anticancer effector cells, such as cytotoxic T cells and NK cells, and at the same time blocks the activity of immunosuppressive cell types such as regulatory T cells and myeloid-derived suppressor cells. These compounds also impact the recruitment of immune cells to the tumor. The phenomena of pattern-recognition receptor tolerance and reprogramming and their implications for immunotherapy are discussed. Finally, novel delivery systems that target the immune-stimulating drugs to the tumor or the tumor-draining lymph nodes to enhance their efficacy and safety are presented.
- Subjects :
- 0301 basic medicine
medicine.medical_treatment
chemical and pharmacologic phenomena
RIG-I-like receptor
03 medical and health sciences
0302 clinical medicine
Immune system
Cancer immunotherapy
Neoplasms
medicine
Animals
Humans
Cytotoxic T cell
Receptors, Immunologic
Receptor
Pharmacology
ddc:615
Toll-like receptor
Innate immune system
business.industry
Toll-Like Receptors
Immunotherapy
biochemical phenomena, metabolism, and nutrition
030104 developmental biology
030220 oncology & carcinogenesis
Cancer research
DEAD Box Protein 58
business
Subjects
Details
- ISSN :
- 10436618
- Volume :
- 154
- Database :
- OpenAIRE
- Journal :
- Pharmacological Research
- Accession number :
- edsair.doi.dedup.....3672ebbc3a040e283aeae3bf8391c0c6